Im­mu­nic's lead MS drug hits pri­ma­ry and key sec­ondary end­points in PhII, but ques­tions re­main

Just a week af­ter its lead pro­gram be­gan en­rolling pa­tients in a study to treat Covid-19, Im­mu­nic Ther­a­peu­tics is mak­ing more waves.

This time, the biotech is pro­vid­ing a glimpse at topline da­ta from a Phase II tri­al study­ing the ef­fi­ca­cy of vid­ofludimus cal­ci­um, or IMU-838, in re­laps­ing-re­mit­ting mul­ti­ple scle­ro­sis pa­tients. Tak­en oral­ly, the can­di­date met its pri­ma­ry end­point in re­duc­ing the cu­mu­la­tive num­ber of com­bined unique ac­tive MRI le­sions af­ter 24 weeks for a 45 mg dose com­pared to a place­bo, as well as a key sec­ondary end­point in such re­duc­tions for the 30 mg dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER